Previous studies have shown that XL888 (HSP90 inhibitor) combined with RFA significantly reduces STAT3 expression and phosphorylation in tumor cells, promotes tumor cell apoptosis, and ameliorates adverse effects of iRFA effectively (128). This evidence concerns the gene STAT3 and neoplasm.